Pfizer Seeks Creation of Federal Docket for Ibrance Patent Infringement Actions



DOCUMENTS
  • Motion


WASHINGTON, D.C. — Pfizer has asked the Judicial Panel on Multidistrict Litigation to create a federal docket for lawsuits in which it has accused 20 generic drug makers of infringing the patent for its breast cancer drug Ibrance, arguing that they all involve the same substantive claims and are seeking the same relief.

In a Feb. 18 motion, Pfizer notes that nine of the 10 actions are pending in the U.S. District Court for the District of Delaware; therefore, it seeks centralization in that district before Judge Colm F. Connolly. The remaining action is pending in the Southern District of …






UPCOMING CONFERENCES




HarrisMartin's MDL Conference: Navigating Current Mass Tort Litigation

November 30, 2022 - New York, NY
The Knickerbocker

MORE DETAILS



HarrisMartin's Webinar Series: The Hottest Upcoming Device Projects - Strattice Hernia Mesh & Exactech Hip Implants

November 09, 2022

MORE DETAILS